Flex Pharma (NASDAQ:FLKS)

CAPS Rating: No stars


How do you think FLKS will perform against the market?

Add Stock to CAPS Watchlist

All Players

2 Outperform
2 Underperform

All-Star Players

0 Outperform
2 Underperform

Wall Street

0 Outperform
0 Underperform

Top FLKS Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Top Bull Pitch

There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches below!

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!


FLKS Summary

Recent Community Commentary

Read the most recent pitches from players about FLKS.


Member Avatar zzlangerhans (99.79) Submitted: 6/2/2016 4:41:56 PM : Underperform Start Price: $13.14 FLKS Score: +104.88

I'm hardly the first to shine a skeptic light on Flex Pharma. Feuerstein dropped an epic takedown at the time of the IPO, and plenty of others have scoffed at the idea of getting vegetable extracts approved to treat muscle spasms. Today, the silliness factor of the company came into focus with their announcement of the availability of an OTC version of their extract called Hotshot. Serious pharmaceutical companies don't delve into the sketchy promotional world of supplements. That's more the style of companies like Star Scientific. At that point, the smell from Flex Pharma's beefcake armpits got bad enough that I decided to add the company to my database and drop a red thumb.

One of my main issues with Flex Pharma is that I can't figure out the company's business plan. They've started trials of a "single molecule" formulation for nocturnal leg cramps after claiming positive results for their vegetable extract earlier this year. What do we know about this single molecule? Not much. Is it a common element of ginger, cinnamon, and bell peppers? Or did the company discover that only one of those ingredients was active? There may be no approved drugs for nocturnal leg cramps in healthy people, but there are plenty of drugs approved for muscle spasms in people with neuromuscular diseases. When Flex gets around to running trials in those conditions, will they use a placebo or active comparator? Through what pathway will they seek approval of their food-derived drug, or will they decide to abort FDA regulation and take the nutraceutical pathway that failed companies like Neuromedix? What are their expectations for the OTC supplement they just began marketing?

I'm sure some of my confusion stems from not having time to read Flex's prospectus or listen to their conference calls. Some of these questions may have been addressed to varying degrees. Nevertheless, I remain very skeptical of Flex's claims as I am of all supposed benefits of food substances to treat medical conditions (e.g. Dr. Oz). Hopefully Flex's share price will continue its upward trajectory from the March low of 6.5 so that it becomes a relatively safe short ahead of what I expect to be underwhelming sales of their OTC supplement.


Find the members with the highest scoring picks in FLKS.

Score Leader


zzlangerhans (99.79) Score: +104.88

Veggies should stay in the produce aisle and not aspire to be pharmaceuticals.

Member Name Member
Call Time
Score Commentary
zzlangerhans 99.79 6/2/2016 Underperform 1Y $13.14 -70.62% +34.25% +104.88 1 Comment
80brown 99.94 6/2/2017 Underperform 5Y $3.63 +6.34% +16.18% +9.85 0 Comment
pbtoau78 59.21 10/28/2016 Outperform 5Y $4.71 -18.05% +32.31% -50.36 0 Comment
jeepdrew < 20 7/14/2015 Outperform 5Y $17.79 -78.30% +34.85% -113.15 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for FLKS.